FDA-approved product exists

Tesamorelin

FDA-approved

Tesamorelin has FDA-approved prescription products (EGRIFTA (BLA022505)). Tesamorelin is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 24 registered ClinicalTrials.gov studies cite Tesamorelin (14 completed, 4 terminated, 3 recruiting, 3 withdrawn); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

What we've verified

Product status: FDA-approved: EGRIFTA (BLA022505)
Still checking: Compounding status, shortage status, safety signals

Verified sources

openFDA Drugs@FDA P0 · retrieved 2026-07-25
503B Bulks List and Interim Categories P0 · retrieved 2026-07-25
ClinicalTrials.gov API v2 P0 · retrieved 2026-07-25

Research and evidence

FDA-approved product exists cite Tesamorelin. Registration is not evidence of approval, efficacy, or safety.

Browse every trial and publication for Tesamorelin →

For developers

JSON record Markdown Source packet